Screener
Alphatec Holdings ATEC Q3 2026 earnings
Reported October 29, 2026 · After market close
Revenue$221.2MMiss by $4.0M
EPS$0.09Miss by $0.01
Revenue estimate$225.2M
EPS estimate$0.10
“Third-quarter revenue fell short of our expectations, primarily due to lower biologics attachment. We own and are addressing that shortfall, and going forward, improving biologics performance is a clear priority for us. At the same time, we continued to see very strong demand for our procedural solutions, with hardware revenue growing 17%, case volumes growing approximately 20%, and new surgeon adoption increasing 25%. These results reinforce our confidence in our procedure-focused strategy and the clinical value of our ecosystem. The disciplined execution of biologics is required to realize full procedural revenue translation, while building the foundation for the longer-term opportunity with OsteoAdapt (Theradaptive). We remain bullish on our ability to make continued progress toward increasingly profitable growth.”
Next report
Date not yet announcedValuation & ratios
Segments
By product
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Alphatec Holdings report Q3 2026 earnings?
- Alphatec Holdings (ATEC) reported Q3 2026 earnings on October 29, 2026 after market close.
- What were Alphatec Holdings's Q3 2026 revenue and EPS?
- Alphatec Holdings reported revenue of $221.2M and eps of $0.09 for Q3 2026.
- Did Alphatec Holdings beat estimates in Q3 2026?
- Revenue missed the consensus estimate of $225.2M by $4.0M. EPS missed the consensus estimate of $0.10 by $0.01.
- How did Alphatec Holdings's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 12.6% from $196.5M a year earlier and eps grew 200.0% from $0.03.
- Where can I find Alphatec Holdings's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-437830) and the 10-Q periodic report (0001193125-26-438050) directly on SEC EDGAR. The filing index links above go to sec.gov.
